BioVaxys Technology Corp. (BIOV.CN)
| Previous Close | 0.0800 |
| Open | 0.0800 |
| Bid | 0.0750 x N/A |
| Ask | 0.0800 x N/A |
| Day's Range | 0.0800 - 0.0800 |
| 52 Week Range | 0.0100 - 0.1000 |
| Volume | |
| Avg. Volume | 154,300 |
| Market Cap | 11.609M |
| Beta (5Y Monthly) | 0.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CNW GroupBioVaxys Technology Corp. Closes First Tranche of Private Placement
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 5,126,574 units (the "Units") of the Company at a price of $0.065 per Unit for aggregate gross proceeds of $333,227.31.
CNW GroupBioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the "MCTO"), by its principal regulator, the Ontario Securities Commission (the "OSC"), under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), following the Company's announcement on February 21, 2024 (the "Default Announcement"), that it was unable to file its audited annual financi
- Baystreet
Stocks in play: BioVaxys Technology Corp
Announces it has appointed Christopher Cherry as Chief Financial Officer. Mr. Cherry, a Chartered Accountant ...
